Inclusion Criteria:
* Voluntary written informed consent obtained prior to any study-related procedures
* Ability to read, understand, and sign the Informed Consent Form and reliably complete required study documents
* Willingness to undergo medical intervention, including genetic therapy, and to comply with the visit schedule and all study procedures
* Commitment to maintain a stable medication and supplement regimen throughout the study, with no initiation of new medications, supplements, or performance-enhancing substances unless approved by the Investigator
* Men and women aged 45-75 years
* Body mass index (BMI) between 17.0 and 30.0 kg/m² at screening
* Evidence of age-related physical decline or sedentary lifestyle defined as:
* \<150 minutes/week of moderate-intensity activity, or
* \<75 minutes/week of vigorous activity, or
* \<600 MET-minutes/week, or
* Clinical Frailty Scale (CFS) score 3-6
* Active Prospera ZEDE eResidency or Physical Residency
* Stable comorbid conditions for at least 3 months prior to screening
* Postmenopausal status (women)
* Willingness to use reliable contraception for 6 months following therapy
* Low or undetectable antibody titers to AAV9 (≤1:100 by ELISA)
Exclusion Criteria:
* Pregnancy, breastfeeding, or intent to become pregnant; premenopausal status (unless ≥12 months amenorrhea or FSH ≥30 IU/L)
* Subjects who have a history of alcohol or drug abuse within 1 year of study entry
* Initiation of prohibited medications, supplements, or interventions during the study period that may confound efficacy or safety assessments
* Active malignancy
* History of malignancy
* Strong family history of cancer in first-degree relatives (≥2 relatives with cancer diagnosed \<60 years)
* Known hereditary cancer syndrome (BRCA1/2, Lynch syndrome, Li-Fraumeni, FAP, HNPCC) without genetic counseling and enhanced surveillance clearance
* History of stroke or transient ischemic attack (TIA)
* History of myocardial infarction (MI) or unstable angina (regardless of time since event)
* Diagnosed coronary artery disease (CAD) documented by coronary angiography or stress testing
* Significant atherosclerotic disease at any location (stenosis ≥50% in carotid, femoral, or other major arteries)
* Prior coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\])
* Prior valvular repair or replacement
* History or current diagnosis of heart failure
* Uncontrolled hypertension (SBP \>140 mmHg or DBP \>85 mmHg despite treatment)
* Left ventricular ejection fraction (LVEF) \<50%, QTc ≥480 ms, or severe valvular heart disease
* Ventricular arrhythmias requiring chronic drug treatment or implantable cardioverter-defibrillator
* Presence of pacemaker or persistent left bundle branch block
* Known diagnosed cardiomyopathy of any etiology
* Significant left ventricular hypertrophy, defined as maximal left ventricular wall thickness ≥15 mm in any segment at end-diastole (by echocardiography or cardiac MRI)
* History of venous thromboembolism (DVT, PE, or thrombosis at any site), particularly if unprovoked, or associated with only minor provoking factors (e.g., minor surgery, combined oral contraceptives, short-term immobilization)
* Recurrent thrombotic events, including recurrent superficial venous thrombosis
* Thrombosis at unusual sites (e.g., mesenteric, portal, or splenic vein thrombosis, Cerebral venous sinus thrombosis, Hepatic vein thrombosis (Budd-Chiari syndrome), Renal vein thrombosis, Retinal vein thrombosis)
* Superior vena cava thrombosis not related to central venous catheterization
* Strong family history of venous or arterial thrombosis at a young age in first-degree relatives
* History of recurrent pregnancy loss or severe obstetric complications suggestive of a hypercoagulable state
* High-degree myopia (≥ -6.0 diopters) or pathological myopia without ophthalmologic clearance
* History of retinal detachment, vitreous hemorrhage, or retinal vascular disease (diabetic retinopathy, retinal vein occlusion, age-related macular degeneration with neovascularization)
* Use of systemic anti-VEGF therapy (e.g., bevacizumab)
* Current use of prohibited medications or supplements (see Section 4.3)
* Fasting plasma glucose ≥6.0 mmol/L (≥108 mg/dL) at screening
* HbA1c ≥6.5% (≥48 mmol/mol) at screening
* Known history of diabetes mellitus (any type)
* History of peptic ulcer disease within 12 months
* Known osteoporosis (DXA T-score ≤ -2.5 at the hip or spine)
* Severe pulmonary disease, including COPD or restrictive lung disease (FVC \<49% predicted)
* Advanced renal disease (CKD stage 3-5, eGFR \<60 mL/min/1.73 m²) or dialysis dependence
* History of cirrhosis or cholestatic liver disease
* Chronic viral hepatitis (HBV, HCV)
* Autoimmune hepatitis
* Active hepatitis or evidence of hepatic decompensation
* ALT or AST \>1.5× upper limit of normal (ULN)
* Total bilirubin \>1.5× ULN (unless due to Gilbert's syndrome)
* Active cholecystitis, symptomatic gallbladder disease (e.g., biliary colic), or any other clinically significant hepatobiliary abnormality
* Neurodegenerative disease
* Neuromuscular disorder
* Psychiatric or movement disorders impairing participation
* History of drug-induced myopathy or rhabdomyolysis
* Elevated creatine kinase (CK) at screening CK \>1.0× ULN confirmed on two separate occasions at least 48 hours apart
* Systemic lupus erythematosus (SLE), including overlap or drug-induced forms
* Mixed connective tissue disease (MCTD)
* Systemic sclerosis (diffuse, limited, or sine scleroderma)
* Inflammatory myopathies (including polymyositis, dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, or overlap myositis)
* Primary Sjögren's syndrome requiring systemic immunosuppression
* Rheumatoid arthritis requiring biologic therapy or with extra-articular manifestations
* Undifferentiated connective tissue disease meeting ≥2 classification criteria
* Current or recent use of immunosuppressive agents (within 3 months)
* Acute bacterial, fungal, or viral infection, fever, or receipt of live vaccines within 30 days prior to screening
* Active hepatitis B infection or reactivation risk (HBsAg positive, HBV DNA detectable, or isolated anti-HBc without anti-HBs)
* Hepatitis C infection (detectable HCV RNA or treatment within 6 months)
* HIV infection
* Active or latent tuberculosis (positive QuantiFERON-TB Gold Plus ≥0.35 IU/mL)
* Acute herpesvirus infection, defined as Active HSV-1 or HSV-2 lesions (vesicles, ulcers, crusts) on clinical examination at screening, CMV or EBV IgM positive
* Platelet count \<100 × 10⁹/L at screening
* Active therapeutic anticoagulation
* Known inherited or acquired coagulation disorder
* Use of anticoagulants that cannot be safely discontinued prior to study treatment
* Severe physical functional limitation (6-Minute Walk Test distance \<150 meters or CFS\>6)
* Prior exposure to any AAV gene therapy product (any AAV serotype)
* Prior exposure to any investigational drug within 90 days
* Participation in another clinical trial within 90 days
* Known hypersensitivity to investigational product components or immunosuppressive agents (e.g., prednisone, rapamycin)
* Life expectancy \<6 months
* Any condition that, in the Investigator's judgment, may pose undue risk, interfere with study outcomes, or impair study participation
